<DOC>
	<DOC>NCT02608710</DOC>
	<brief_summary>The purpose of this study is to examine the pharmacokinetic and pharmacodynamic effect of RDEA3170 when given as single or multiple doses</brief_summary>
	<brief_title>RDEA3170 PK/PD Study</brief_title>
	<detailed_description />
	<criteria>Subject has a body weight ≥ 50 kg (110 lbs.) and a body mass index ≥ 18 and ≤ 40 kg/m2. Subject has a Screening serum urate level 4 to 7 mg/dL Subject is free of any clinically significant disease or medical condition, per the Investigator's judgment. Subject has a history or suspicion of kidney stones. Subject has undergone major surgery within 3 months prior to Screening. Subject donated blood or experienced significant blood loss within 12 weeks prior to Day 1 or gave a plasma donation within 4 weeks prior to Day 1. Subject has clinically unacceptable physical examination, per the Investigator's judgment. Subject has clinically relevant abnormalities in blood pressure, heart rate, or body temperature, per the Investigator's judgment. Subject has Screening clinical safety laboratory parameters (serum chemistry [other than serum creatinine and serum urate], hematology, coagulation or urinalysis) that are outside the normal limits and are considered clinically significant by the Investigator. Subject has a serum creatinine value above the upper limit of normal at the Screening visit. Subject has clinically relevant abnormalities in 12lead electrocardiogram, per the Investigator's judgment. Subject has a history of cardiac abnormalities Subject has received any strong or moderate enzymeinducing drug or product within 2 months prior to Day 1.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>